MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
66.13
-0.87
-1.30%
After Hours: 66.13 0 0.00% 16:57 03/27 EDT
OPEN
67.43
PREV CLOSE
67.00
HIGH
67.60
LOW
65.80
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
87.50
52 WEEK LOW
35.95
MARKET CAP
5.47B
P/E (TTM)
8.50
1D
5D
1M
3M
1Y
5Y
1D
Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance?
Simply Wall St · 13h ago
A Look At PTC Therapeutics (PTCT) Valuation As Shares Reflect Mixed Recent Returns
Simply Wall St · 2d ago
PTC Therapeutics files initial beneficial ownership statement; Director Jessica Caroline Chutter reports no securities beneficially owned
Reuters · 2d ago
PTC Therapeutics Adds Veteran Banker to Board
TipRanks · 3d ago
Press Release: PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
Dow Jones · 3d ago
PTC Therapeutics appoints Jessica Chutter to board; Chutter retires from Morgan Stanley after 40 years
Reuters · 3d ago
PTC THERAPEUTICS APPOINTS BIOTECH BANKING PIONEER JESSICA CHUTTER TO BOARD OF DIRECTORS
Reuters · 3d ago
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
PR Newswire · 3d ago
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.